Cheap Indian Drugs Spur Rare Congressional Bipartisanship
It looks as if we have a sighting of that rare Washington, D.C., unicorn: bipartisan agreement in the halls of Congress. Democrats and Republicans have united in defense of Big Pharma and are lobbying the Obama administration and State Department to pressure India's generic-drug policies.
In this video, health-care analyst David Williamson discusses what has Congress riled up, the importance of India as a growth driver for the pharma industry, and whether investors need to start taking precautions with their portfolios.
Rising health-care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.
Follow David on Twitter: @MotleyDavid.
The article Cheap Indian Drugs Spur Rare Congressional Bipartisanship originally appeared on Fool.com.
David Williamson owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
